The Wayback Machine - https://web.archive.org/web/20180927005555/https://adisinsight.springer.com/drugs/800007434

Ibutamoren

Next Previous
Drug Profile

Ibutamoren

Alternative Names: Ibutamoren mesilate; Ibutamoren mesylate; L 163191; MK-0677; MK-677; Oratrope™

Latest Information Update: 18 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Developer Ammonett Pharma; Merck & Co
  • Class Indoles; Small molecules; Spiro compounds
  • Mechanism of Action Growth hormone releasing factor agonists; Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Somatotropin deficiency
  • No development reported Fibromyalgia; Muscular atrophy
  • Discontinued Alzheimer's disease; Fracture; Postmenopausal osteoporosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 19 Jun 2017 Ibutamoren receives Orphan Drug status for Somatotropin deficiency (In children) in USA
  • 25 May 2017 Ammonett Pharma receives Notice of allowance for ibutamoren in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top